Kamada (KMDA) Q1 2026 earnings review
Distribution Bails Out Core Weakness as R&D Cuts Prop Up Profits
Kamada delivered 3% YoY revenue growth in 26Q1, but the headline masks a concerning mix shift. The core Proprietary Products segment reversed into a 10% decline ($36.2M vs $40.0M YoY), driving gross margins down 500 basis points. Management attributed the weakness to a temporary single-order shipment delay, reiterating aggressive double-digit full-year guidance. Net Income grew 4% YoY, but the quality of these earnings is poor: profitability was entirely sustained by a 49% cut to R&D expenses following the termination of the InnovAATe clinical trial. The bright spot remains the Distribution segment, which is accelerating rapidly (+125% YoY) on the back of recent biosimilar launches.
🐂 Bull Case
The Distribution business is accelerating massively, growing 125% YoY to $9.0M. Fueled by new biosimilar launches in Israel, it is shifting from a side business to a primary growth engine.
Despite a sluggish Q1, management confidently reaffirmed FY26 revenue guidance of $200M-$205M (+12% YoY) and Adj. EBITDA of $50M-$53M (+23% YoY), implying strong sequential growth for the rest of the year.
🐻 Bear Case
Proprietary sales dropped 10% YoY. Because this segment carries higher margins, consolidated gross margin decelerated sharply from 47% to 42%, squeezing operating leverage.
Gross Profit fell by $1.6M YoY. Net Income only grew because R&D expenses were slashed by $2.1M. Financial engineering via trial cancellation is not a sustainable long-term profit driver.
⚖️ Verdict: ⚪
Neutral. The underlying thesis of expanding the Distribution segment and ramping up plasma centers is intact. However, the heavy reliance on an R&D cut to manufacture earnings growth this quarter, combined with core revenue contraction, warrants caution until the promised Q2 rebound materializes.
Key Themes
Quality of Earnings Alert: R&D Cuts Mask Gross Profit Decline
Kamada reported flat Adjusted EBITDA ($11.6M) and slightly higher Net Income ($4.1M), presenting a narrative of 'profitable growth'. However, the data contradicts this. Gross Profit actually fell by $1.6M YoY due to the unfavorable mix shift. The bottom line was rescued exclusively by a 49% reduction in R&D expenses ($2.2M vs $4.2M YoY) following the termination of the Phase 3 InnovAATe clinical trial. Relying on halted innovation to protect margins is a reversing dynamic that investors should heavily discount.
Distribution Segment Accelerating Fast
The Distribution segment is unequivocally the star of the quarter. Revenues surged 125% YoY from $4.0M to $9.0M, drastically outperforming the core business. This acceleration is driven by the successful launch of biosimilar products in the Israeli market (primarily sourced from Alvotech). With additional launches slated and expansion into the MENA region underway, management's 5-year target of $15M-$20M annual sales from the biosimilar portfolio appears increasingly conservative.
Proprietary Products Reversing Direction
Sales of the Proprietary Products segment (KEDRAB, GLASSIA, CYTOGAM) contracted by 9.5% YoY to $36.2M. Management explicitly blamed a 'temporary shipment delay of a single order' that was fulfilled in April. While this provides a plausible alibi, this segment has historically been the high-margin anchor. Its weakness directly caused the consolidated gross margin to decelerate from 47% to 42%.
Vertical Integration: San Antonio Plasma Center Approved
Kamada announced FDA approval for its San Antonio, TX plasma collection center following a February 2026 inspection. This center is now cleared for commercial sales of normal source plasma. This is a critical milestone for their vertical integration strategy. Along with the Houston center, these facilities are expected to generate $8M-$10M in annual revenue each at peak capacity while securing the supply chain for specialty plasma products.
Other KPIs
Stable YoY. Despite gross margins decelerating by 500 basis points due to the heavier mix of lower-margin Distribution sales, operating discipline and the severe cut to R&D kept the Adjusted EBITDA margin robust and exactly in line with Q1 2025.
Stable. The slight cash burn is consistent with prior first quarters (-$0.5M in 25Q1) and largely reflects seasonal working capital needs. Inventory increased to $85.4M (from $78.4M at year-end), likely reflecting the delayed Proprietary shipment and ramp-up of Distribution products.
Slightly down from $75.5M at the end of FY25. Note that this balance does not yet reflect the $14.4M dividend payment made on April 7, 2026. This leaves Kamada with roughly $58.7M in pro-forma cash to execute on its stated M&A objectives.
Guidance
Accelerating. The midpoint of $202.5M implies a 12% YoY growth rate over FY25's $180.5M. Given that Q1 grew only 3%, hitting this guidance will require significant acceleration in Q2-Q4, heavily relying on the recovery of the delayed Proprietary order and continued Distribution momentum.
Accelerating. The midpoint of $51.5M implies a massive 23% increase over FY25's $42.0M. With Q1 EBITDA flat YoY, the company needs to average over $13M per quarter for the rest of the year. This suggests management expects the favorable R&D cost structure to persist while Proprietary margins rebound.
Key Questions
Margin Impact of Segment Mix
Distribution sales are growing at 125% while Proprietary sales declined. If this mix shift becomes structural rather than temporary, what is the new normalized gross margin we should model for the consolidated business?
Reinvestment of R&D Savings
With the InnovAATe trial terminated, R&D expenses fell nearly 50%. Is this the new baseline run-rate for R&D, or do you plan to redeploy these funds into post-marketing studies (like CYTOGAM) or new pipeline assets later this year?
M&A Capital Allocation
Post the April dividend payment, pro-forma cash sits around $58.7M. Given the delayed timeline for executing a commercial-stage M&A transaction, do you have sufficient capital to close a meaningful deal without external financing?
Details of the Shipment Delay
You cited a single delayed order as the reason for the Proprietary segment's decline. Can you quantify the exact dollar value of this order and confirm that 100% of it was recognized in April?